Glaxosmithkline Regulatory News (GSK)

Outcome and Vesting Level

Portion of the Award

Measure and Outcome

% of maximum

% of award

1/3rd

Adjusted Free Cash Flow - For the three-year period, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £14.53bn, which is above the level of £13.20bn required for maximum vesting. 

Adjustments to the original target and vesting schedule were communicated in the 2020 Annual Report and will be set out in the 2021 Annual Report.

100

33.33

1/3rd

Total Shareholder Return - For the three years ending 31 December 2021, the Company's Total Shareholder Return ranked 10th, which is below the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK.

0

0

1/3rd

R&D New Products - For the three-year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of £11.12bn, which is slightly below the level of £11.14bn required for 75% vesting. The threshold vesting level was £10.02bn. 

74

24.66

Total vesting for 2019 award

Lapsed

58

42

57.99

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

274,480

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I Mackay

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

152,815

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The number of ADSs vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.00

146,831

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.3404

79,172

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Vaccines and Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

119,780

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Vaccines and Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary Shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

56,297

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Following the vesting on 16 February 2022 of awards granted in 2019 under the Company's 2017 Performance Share Plan, Ms Conrad will receive a cash payment of £126,710.48 less applicable tax withholding in respect of 8,006 notional ordinary shares.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

8,006

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP and General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The number of ADSs vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.00

46,446

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP and General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.3404

21,830

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

8,006

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

3,763

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

3,780

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

1,777

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The number of ADSs vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.00

67,075

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.3404

33,974

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

134,163

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

4,008

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Ramakrishnan

b)

Position/status

Chief Technology and Digital Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The number of ADSs vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.00

4,558

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Ramakrishnan

b)

Position/status

Chief Technology and Digital Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$43.3404

2,444

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

110,567

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

51,967

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

64,497

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

30,314

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

50,497

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

23,734

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO, ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

10,978

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO, ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

5,160

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The number of Ordinary Shares vesting on awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£0.00

8,006

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2019 under the Company's 2017 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.8269

3,763

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-02-16

f)

Place of the transaction

London Stock Exchange (XLON)